Clicky

Aptose Biosciences Inc.(APS) News

Date Title
Jul 1 Aptose Upgraded to Trade on OTCQB Market
Jun 30 Aptose Announces Deferral of Interest Payment
Jun 20 Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
Jun 17 Aptose Provides Corporate Updates
Jun 12 Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
May 20 Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
Apr 23 Aptose Announces Auditor Not Standing for Re-Appointment
Apr 23 Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Feb 20 Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Feb 18 Aptose Announces Reverse Share Split
Jun 14 Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Jun 13 Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
May 6 Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
Jan 31 Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
Jan 29 This Aptose Biosciences Insider Increased Their Holding In The Last Year
Nov 30 Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
Nov 2 Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
Oct 23 Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
Aug 24 Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference